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Viola C. Y. Chow,* Mamie Hui,* Alan Wu,* 
Nelson Lee,* Florence H. Y. Yap,* 
Frankie W. T. Cheng,* Joseph J. Y. Sung,* 
and John S. Tam*
We evaluated an indirect immunofluorescence assay
based on virus-infected cells for detecting anti–severe acute
respiratory syndrome-associated coronavirus (SARS-CoV)
immunoglobulin (Ig) G antibody. All confirmed SARS cases
demonstrated seroconversion or fourfold rise in IgG anti-
body titer; no control was positive. Sensitivity and specifici-
ty of this assay were both 100%. Immunofluorescence
assay can ascertain the status of SARS-CoV infection. 
On March 12, 2003, the World Health Organization(WHO) issued a global alert on outbreaks of atypical
pneumonia (1). Cases were observed in Vietnam, Hong
Kong, Singapore, and Toronto. As of June 2003, a total of
29 countries had been affected (2). WHO refers to this
highly infectious disease as severe acute respiratory syn-
drome (SARS) and has formulated case definitions for sur-
veillance (3). The virus causing SARS was identified in
late March (4–6). The full genome of a few strains of the
SARS-associated coronavirus (SARS-CoV) was soon
available; it was confirmed to be a novel virus phylogenet-
ically distinct from previous known coronaviruses (7,8).
Since the discovery of SARS-CoV, laboratory diagnosis
for the infection has become an important part of patient
management, contact tracing, and epidemiologic study. In
general, serology is the mainstay for ascertaining viral
infection status. We report the evaluation of a first-genera-
tion assay based on the indirect immunofluorescence tech-
nique for detecting anti-SARS-CoV immunoglobulin (Ig)
G antibody.
The Study
We conducted this study at the teaching hospital of the
Chinese University of Hong Kong, Prince of Wales
Hospital, where a major outbreak of SARS had occurred
(9). Patients admitted with clinical features suggestive of
SARS were investigated for SARS-CoV infection by a
combination of methods including direct detection of viral
RNA by reverse-transcription polymerase chain reaction
(RT-PCR) using primers COR1/COR2 (10), virus isolation
using African green monkey kidney (Vero) cells, and serol-
ogy. All RT-PCR–positive results were confirmed by
repeat testing from the original sample; isolation positive
results were confirmed by detection of SARS-CoV RNA
from culture supernatant by RT-PCR.
True SARS Cases
For the purpose of study analysis, a patient was defined
as a true SARS case when he or she had the following two
conditions: 1) fulfilled the WHO criteria of a probable case
of SARS (11), and 2) had one or more specimens positive
for SARS-CoV by RT-PCR, isolation, or both. From
March to May 2003, we identified 128 patients who ful-
filled our definition of a true SARS case. Sixteen of them
died before a convalescent-phase blood sample could be
collected; 9 received convalescent-phase plasma therapy.
These 25 cases were excluded. As a result, 103 true SARS
cases were analyzed. Three were pediatric patients of ages
5, 11, and 16 years. Eighty-six were adults from 21 to 64
years of age (mean 35.7, SD 11.3), 60.5% were female.
The remaining 14 were elderly patients 66 to 89 years
(mean 75.6, SD 7.8), 50.0% female. Pneumonia developed
in all these patients; five required intensive care and even-
tually recovered; four died of the infection.
Non-SARS Controls
Patients admitted to the Prince of Wales Hospital dur-
ing 2000 for respiratory tract infections or febrile illnesses
were used as non-SARS controls. The convalescent-phase
serum samples that had been collected from these patients
for viral and atypical pneumonia serologic screening were
retrieved for this study. This control group consisted of 540
patients; 126 were pediatric patients 6 months to 15 years
of age (mean 7.4, SD 3.1); 40.0% were girls. Of the 308
adults ages 16–65 years (mean 45.6, SD 10.3); 35.3% were
female. For the 106 controls 65–86 years of age (mean
73.2, SD 3.7), 65.0% were female. Overall, 16.3% of this
control group were confirmed to have infections with res-
piratory viruses or atypical pathogens.
In addition to hospitalized patients, a healthy group was
included as non-SARS controls. This group comprised 635
medical students 19–31 years of age (mean 23.5, SD 2.2);
41.9% were female. Their blood samples, which had been
submitted for pre–varicella-zoster virus vaccination
screening in 2000, were retrieved for this study.
Antibody Detection
Anti-SARS-CoV IgG antibody was detected by the
indirect immunofluorescence technique. Vero cell mono-
layer at 90% confluence was inoculated with SARS-CoV.
The coronavirus stock used was the third passage of an iso-
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late grown from a SARS patient. The full genome
sequence of this isolate has been published (GenBank
accession no. AY278554). Infected cells were harvested
when cytopathic effect was observed on 70% of the cell
monolayer. With our laboratory conditions, this event
occurred consistently at 96 to 100 hours after virus inocu-
lation. Infected cells were mixed with noninfected Vero
cells at a ratio of 1 to 1. After being washed three times
with phosphate-buffered saline (PBS), cells were spotted
onto 12-well, Teflon-coated glass microscope slides. The
slides were allowed to air-dry and then fixed for 10 min-
utes with 100% pre-chilled acetone, and stored at –70°C
until use.
Serum samples were heat-inactivated at 56°C for 30
minutes and then diluted in PBS. An aliquot of 25-µL
diluted serum sample was placed on a coated well and
incubated at 37°C for 30 minutes in a moist chamber. After
being washed three times with PBS, a fluorescein isothio-
cyanate–conjugated rabbit anti-human IgG antibody
(Dako, Denmark) was added at a dilution of 1 to 40, and
incubated for 30 minutes at 37°C. In each test run, a posi-
tive control serum with known titer was tested in twofold
serial dilutions to guard the sensitivity, and results were
crosschecked by two experienced technicians.
Our diagnostic approach was to perform a screening
test at a dilution of 1 to 40 for serum samples collected at
>10 days after the onset of illness. Upon special circum-
stances, testing might be performed on earlier samples.
When the screening result was positive, a follow-up test at
twofold serial dilutions starting from 1 to 40 was per-
formed together with the corresponding acute-phase serum
sample. On the other hand, if the screening result was neg-
ative or showed nonspecific fluorescent signals, a follow-
up sample was collected for repeat testing. In addition,
when a titer of 1:40 was obtained on the second sample, a
third sample was collected for repeat testing. A serocon-
version or fourfold rise in antibody titer was regarded as
serologic evidence of recent SARS-CoV infection.
The serologic data of the true SARS cases used for this
analysis were based on the results obtained from our rou-
tine test runs. During the outbreak, our laboratory-per-
formed screening test are conducted on every alternate
day, and follow-up titration tests occur the next day. The
samples included in each test run were based on clinicians’
requests containing a variable proportion of cases that
turned out to be non-SARS; the technicians did not know
the results of other SARS investigations for the testing
samples. For the non-SARS controls, each test run con-
tained 50 testing samples mixed with 5 known positive
controls and was tested in a blind fashion.
Conclusions
A total of 212 serum samples from the 103 true SARS
cases were tested for anti–SARS IgG antibody. Four sam-
ples (1.9%) showed fluorescent signals from all cells fixed
on the slide. Since we had mixed infected cells with an
equal amount of noninfected cells, we expected to observe
genuine positive signals from approximately 50% of cells
fixed on the slide. Therefore, these four samples were
regarded as nonspecific. Follow-up samples were obtained
from these patients, and all tested positive. Overall, 94
(91.3%) cases showed seroconversion, and 9 (8.7%)
showed a fourfold rise in antibody titer. The positive rate
and antibody titer with respect to the time of specimen col-
lection are shown in the Table. We detected the earliest
seroconversion on day 6 after the onset of fever. The anti-
body-positive rates for samples collected during days
5–10, 11–15, and 16–20 after the onset of fever were
34.3%, 78.3%, and 97.7%, respectively.
Of the 1,175 samples obtained from the non-SARS
control groups, 24 (2.0%) showed fluorescent signals from
all cells fixed on the slide. These samples were regarded as
nonspecific. The remaining 1,151 samples were negative
for anti–SARS IgG antibody.
Serologic diagnosis remains an indispensable means
for confirming viral infection status. Antibody assays
based on virus-infected cells or whole viral lysate might
produce cross-reactivity between infections because of
closely related viruses. As common cold–associated coro-
navirus infections are highly prevalent, the specificity of
whole virus-based assays for the diagnosis of SARS-CoV
infection is a concern. Our results indicated that an infect-
ed cell-based indirect immunofluorescence test for anti-
SARS IgG antibody provided a sensitivity and specificity
of 100%. However, this immunofluorescence test is rela-
tively labor intensive. Experienced technicians are
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Table. Anti-SARS-CoV IgG positive rate and titer according to time of blood sample collectiona 
Time of sample collection after 
onset of fever No. of samples tested 
No. (%) of samples with anti–SARS 
IgG antibody detected 
Anti-SARS IgG antibody titer, range 
(mode) 
1–5 days 64 0 – 
6–10 days 35 12 (34.3) 40–320 (160) 
11–15 days 23 18 (78.3) 40–640 (320) 
16–20 days 43 42 (97.7) 40–2,560 (640) 
21–37b days 47 47 (100) 80–5,120 (640) 
aSARS, severe acute respiratory syndrome; CoV, coronavirus; IgG, immunoglobulin G; –, not applicable. 
bMedian collection time: 22 days; interquartile range: 4 days. 
required to examine the results, in particular to differenti-
ate nonspecific signals from positive results. These proper-
ties make the test not ideal for large-scale studies.
Nevertheless, its high sensitivity and specificity make the
test applicable to ascertain infection status and to serve as
a reference for assessing the performance of high-through-
put second-generation assays such as enzyme immunoas-
say. The immunofluorescence test can also be used as a
confirmatory assay for samples reactive to screening
assays. Further development of more feasible assays with
high throughput and performance should be pursued.
Evaluation of the role of other classes of anti–SARS-CoV
antibodies in the diagnosis of SARS-CoV infection is
needed.
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